Dec 31, 2025 • DOTmed
BULLISH
GE HealthCare to supply 300 CT scanners in Indonesia
GE HealthCare will supply over 300 CT scanners to public hospitals across Indonesia, as part of the Strengthening Indonesia’s Health Referral Network (SIHREN) program to expand access to advanced diagnostics. This initiative aims to reach 280 million Indonesians, particularly in remote regions, by modernizing the national referral system and improving healthcare infrastructure. The company is also supporting this effort with a new production facility in Bogor and a training hub in Jakarta.
Dec 31, 2025 • The Globe and Mail
NEUTRAL
Barclays Keeps Their Hold Rating on Johnson & Johnson (JNJ)
Barclays analyst Matt Miksic reiterated a Hold rating on Johnson & Johnson (JNJ) with a $217.00 price target. This comes as the company reported strong Q3 revenues of $23.99 billion and a net profit of $5.15 billion, exceeding last year's figures. Insider sentiment is neutral, though one director recently purchased 1,250 shares.
Dec 31, 2025 • The Globe and Mail
NEUTRAL
Barclays Keeps Their Hold Rating on Johnson & Johnson (JNJ)
Barclays analyst Matt Miksic maintained a Hold rating on Johnson & Johnson (JNJ) with a $217.00 price target, and Goldman Sachs maintained a Buy rating. The company reported quarterly revenues of $23.99 billion and a net profit of $5.15 billion for the quarter ending September 28. Corporate insider sentiment on the stock is neutral, despite a recent insider purchase.
Dec 31, 2025 • openPR.com
SOMEWHAT-BULLISH
Japan Nucleic Acid Isolation and Purification Market is Driven by Biotech Research and Genomic Advancements | Top Companies - MP Biomedicals, Illumina Inc., General Electric Company
The Japan Nucleic Acid Isolation and Purification Market is projected to grow at a CAGR of 4.8% from 2024 to 2031, driven by advancements in biotech research and genomics. Key market players include MP Biomedicals, Illumina Inc., and General Electric Company. Recent industry developments in Japan highlight innovations in rapid viral RNA extraction, automated nucleic acid isolation, magnetic bead kits for mRNA vaccine QC, and customization centers for extraction reagents.
Dec 30, 2025 • AD HOC NEWS
SOMEWHAT-BULLISH
Revvity Inc.: Quiet Re?Rating Story in a Volatile Diagnostics Market
Revvity Inc., a life-sciences and diagnostics company, is undergoing a quiet rerating as it reinvents itself post-PerkinElmer divestiture. The company has been tightening its portfolio, integrating acquisitions, and focusing on genomics, diagnostics, and analytical technologies. Investors are slowly becoming more constructive, with the stock showing a gradual uptrend driven by improved earnings visibility and strategic reset.
Dec 30, 2025 • MarketBeat
NEUTRAL
Mirova US LLC Has $219.47 Million Position in Edwards Lifesciences Corporation $EW
Mirova US LLC has reduced its stake in Edwards Lifesciences Corporation by 3.7%, valuing its remaining 2.8 million shares at approximately $219.47 million, making it their 20th largest holding. Despite recent insider selling, Edwards Lifesciences exceeded quarterly EPS and revenue estimates, prompting analyst upgrades and a "Moderate Buy" consensus rating with a $93.95 price target. The company also provided optimistic FY2025 EPS guidance, signaling strong financial performance moving forward.